Skip to main content

Development of a new CRISPR-Cas3-based tool for large genomic deletions


The advent of the revolutionary genome editing technique CRISPR-Cas9 has enabled targeted gene mutation, repression, and activation, facilitating impactful biological findings. However, Cas9 as an unbiased DNA deletion tool is limited in its ability to interrogate large regions of DNA of unknown function, because it predominantly generates very small (<20 bp) insertions and deletions at its target site. The capacity to rapidly and efficiently generate large genomic deletions does not currently exist and would be an extremely useful tool for research, allowing for rapid strain engineering of bacterial cells for synthetic biological and metabolic engineering purposes. Additionally, this technology would allow for the interrogation of large segments of non-coding DNA in human cells, much of which has unknown function, but whose variants are often associated with human disease. In this proposal, I aim to develop a Type I-C CRISPR-Cas system employing the Cas3 enzyme (completely distinct from Cas9), which naturally possess coupled nuclease and helicase activity, for high-throughput gene-editing purposes in various prokaryotic, as well as human cells. My preliminary results have shown that this is a credible approach, as I have been able to generate individually, as well as in combination, multiple deletions in bacterial organisms exceeding 60 kb in size. A focal point of the proposal is to adapt this system for use in human cells, which would provide a novel basic research tool with unprecedented capabilities and also could be utilized in human health-related applications. The proposal aims to address this later possibility by utilizing the developed system to treat human cell lines infected with difficult-to-treat pathogenic viruses.

Field of science

  • /natural sciences/biological sciences/genetics and heredity/dna
  • /natural sciences/biological sciences/microbiology/bacteriology
  • /engineering and technology/industrial biotechnology/metabolic engineering

Call for proposal

See other projects for this call

Funding Scheme

MSCA-IF-GF - Global Fellowships


Meyerhofstrasse 1
69117 Heidelberg
Activity type
Research Organisations
EU contribution
€ 264 669,12

Partners (1)

United States
Franklin Street 1111, 12 Floor
94607 Oakland Ca
Activity type
Higher or Secondary Education Establishments